SenL-T7 CAR T Cells (Hebei Senlang Biological)

N/A

Report date: 2025/09/30 20:00:06

Base Information

Drug NameSenL-T7 CAR T Cells (Hebei Senlang Biological)
Drug Alias NameSenl-T7Senl-T-7SENL-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitorsGene transference
TargetsT-cell antigen CD7
Therapy Area/IndicationsT lymphoblastic lymphomaLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsT lymphoblastic lymphomaLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A